Core Viewpoint - The major shareholders of Shanghai Bid Pharmaceutical Technology Co., Ltd. plan to reduce their holdings due to liquidity needs, with specific details on the number of shares and methods of reduction outlined in the announcement [1][2][4]. Shareholder Information - The major shareholder, Zhoushan Xinxie Enterprise Management Partnership (Limited Partnership), holds 5,019,806 shares, accounting for 5.52% of the total shares [1][2]. - Another shareholder, Ningbo Landan Enterprise Management Partnership (Limited Partnership), holds 4,305,076 shares, representing 4.74% of the total shares [3][4]. - The total shares held by Zhoushan Xinxie, Ningbo Landan, and their associated party, Wu Bo, amount to 11.12% of the company [1][4]. Reduction Plan Details - Zhoushan Xinxie plans to reduce up to 908,829 shares, not exceeding 1.00% of the total share capital, through block trading [2][5]. - Ningbo Landan also intends to reduce up to 908,829 shares, with the same percentage limit and method [2][5]. - Wu Bo plans to reduce up to 785,804 shares through centralized bidding, which is 0.86% of the total shares [2][5]. Reduction Timeline - The reduction period is set from September 29, 2025, to December 28, 2025 [5][6]. Shareholding Source - The shares held by Zhoushan Xinxie and Ningbo Landan were acquired before the company's initial public offering (IPO) and through capital reserve conversion [2][4]. - Wu Bo's shares were obtained through a non-trading transfer after the dissolution of the original shareholder, Dinghua Yongchuan Venture Capital Partnership (Limited Partnership) [4][5]. Compliance and Commitments - The major shareholders have made commitments regarding their shareholding, including a lock-up period for shares acquired before the IPO [6][7]. - The shareholders will comply with relevant laws and regulations during the reduction process, ensuring that the actions do not affect the company's governance structure or control [10][11].

Core Viewpoint - Bid Pharma (688073.SH) announced that its shareholders Zhoushan Xinxie, Ningbo Landan, and their concerted action person Mr. Wu Bo plan to reduce their holdings in the company [1] Shareholder Reduction Plans - Zhoushan Xinxie intends to reduce its shareholding by no more than 908,800 shares through block trading, which accounts for no more than 1.00% of the company's total share capital [1] - Ningbo Landan also plans to reduce its shareholding by no more than 908,800 shares through block trading, representing no more than 1.00% of the company's total share capital [1] - Shareholder Wu Bo plans to reduce his shareholding by no more than 785,800 shares through centralized bidding, which is no more than 0.86% of the company's total share capital [1]

Group 1 - Baoti shares: The controlling shareholder has increased its stake by 1.004% [1] - Chengda Pharmaceutical: Qianhai Shengtai plans to reduce its holdings by 7.27% [1] - Huawu Co., Ltd.: Nie Jinghua and others plan to reduce their holdings by no more than 3% within three months [1] Group 2 - Changjiang Materials: The controlling shareholder plans to reduce its holdings by no more than 3% [1] - Weishi Electronics: The controlling shareholder's reduction plan does not exceed 3% [1] - Jialian Technology: A related party plans to reduce its holdings by 2.6166% within three months [1] Group 3 - Funeng Technology: Shareholders plan to reduce their holdings by no more than 2% [1] - Lanfeng Biochemical: Hainan Wenqin reduced its holdings by 2.00% [1] - Koweil: Shareholders Jingkun Investment and Hetu Investment plan to reduce their holdings by no more than 2.34% [1] Group 4 - Huayin Power: Hunan Energy plans to reduce its holdings by 1% [1] - Bid Pharmaceutical: Zhoushan Xinxin plans to reduce its holdings by 1.00% [1] - Guanhao High-tech: Shareholder Yuechuang Investment plans to reduce its holdings by no more than 1% [1] Group 5 - Juxin Technology: Zhuhai Chenyour plans to reduce its holdings by no more than 0.5% [1] - Tianji Shares: Shantou Tianji reduced its holdings by 0.61% [1]

Group 1 - Bid Pharma announced a shareholder reduction plan due to liquidity needs, with shareholders Zhoushan Xinxie, Ningbo Landan, and Mr. Wu Bo planning to reduce their holdings within three months after the announcement [1] - Zhoushan Xinxie and Ningbo Landan plan to reduce up to approximately 908,800 shares each, representing no more than 1% of the total share capital, while Mr. Wu Bo plans to reduce up to approximately 785,800 shares, representing no more than 0.86% of the total share capital [1] - The reduction price will be determined based on the market price at the time of the reduction [1] Group 2 - As of the report, Bid Pharma's market capitalization is 5.9 billion [2]

Group 1 - The core point of the article is that Bid Pharma (688073) announced a plan for its shareholders to reduce their stake in the company by up to 2.86% of the total share capital within three months through various trading methods [1] Group 2 - The shareholders involved in the reduction are Zhoushan Xinxie Enterprise Management Partnership and its concerted parties, Ningbo Landan Enterprise Management Partnership and Wu Bo [1] - The total number of shares to be reduced is up to 2.6035 million shares [1]

Core Viewpoint - Bid Pharma (688073.SH) announced a share reduction plan by its shareholders due to personal liquidity needs, which may impact the stock price and market perception of the company [1] Shareholder Reduction Plan - Shareholder Zhoushan Xinxie plans to reduce up to 908,829 shares through block trading, representing 1.00% of the total share capital [1] - Shareholder Ningbo Landan also intends to reduce up to 908,829 shares through block trading, equivalent to 1.00% of the total share capital [1] - Shareholder Wu Bo aims to reduce up to 785,804 shares through centralized bidding, accounting for 0.86% of the total share capital [1] - The reduction prices will be determined based on the market prices at the time of execution [1]

证券代码：688073 证券简称：毕得医药 公告编号：2025-077 上海毕得医药科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 截至本公告披露日，上海毕得医药科技股份有限公司（以下简称"毕得医药" 或"公司"）股东舟山欣曦企业管理合伙企业（有限合伙）（以下简称"舟山欣曦"） 持有公司无限售条件流通股 5,019,806 股，占公司股份总数的 5.52%。股东宁波 兰旦企业管理合伙企业（有限合伙）（以下简称"宁波兰旦"）持有公司股份 4,305,076 股，占公司股份总数的 4.74%，其中 69,486 股为有限售条件流通股， 4,235,590 股为无限售条件流通股。股东吴波持有公司无限售条件流通股 785,804 股，占公司股份总数的 0.86%。舟山欣曦、宁波兰旦、吴波系一致行动人，合计 持有毕得医药 11.12%的股份。 1 总股本的 1.00%；股东吴波拟通过集中竞价交易方式减持公司股份数量不超过 785,804 股，即 ...

智通财经APP讯，毕得医药(688073.SH)公告，公司股东舟山欣曦、宁波兰旦及其一致行动人吴波先生 计划减持其所持有的公司股份。其中，舟山欣曦拟通过大宗交易方式减持公司股份数量不超过90.88万 股，即不超过公司总股本的1.00%;宁波兰旦拟通过大宗交易方式减持公司股份数量不超过90.88万股， 即不超过公司总股本的1.00%;股东吴波拟通过集中竞价交易方式减持公司股份数量不超过78.58万股， 即不超过公司总股本的0.86%。 ...

毕得医药公告，股东舟山欣曦计划2025年9月29日至2025年12月28日以大宗交易方式减持不超过90.88万 股，占公司总股本1.00%；股东宁波兰旦同期拟以大宗交易方式减持不超过90.88万股，占1.00%；股东 吴波同期拟以集中竞价方式减持不超过78.58万股，占0.86%。三方目前合计持股11.12%，本次减持因资 金需要。 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The company has shown a strong recovery in its main business, with significant revenue growth and improved profitability metrics. The revenue for the first half of 2025 reached 628 million yuan, a year-on-year increase of 17.91%, while the net profit attributable to the parent company was 73.41 million yuan, up 41.60% year-on-year [4][5] - The company is expected to continue its growth trajectory, with projected revenues of 1.31 billion yuan, 1.58 billion yuan, and 1.92 billion yuan for 2025, 2026, and 2027 respectively, reflecting growth rates of 19.27%, 20.30%, and 21.22% [3][5] Summary by Sections Financial Performance - In 2025, the company achieved a revenue of 1,091.86 million yuan, with a year-on-year growth rate of 30.94% [3] - The net profit attributable to the parent company for 2025 is forecasted to be 145.17 million yuan, representing a growth rate of 23.63% [3] - The gross margin for the first half of 2025 was 44.25%, an increase of 4.74 percentage points year-on-year [5] Business Segments - The drug molecule block business generated 520 million yuan in revenue for the first half of 2025, a growth of 14.35%, while the scientific reagent business saw revenue of 40.73 million yuan, up 87.60% [5] - The company is expanding its product lines and maintaining a stable market share in the drug molecule block sector, contributing to its revenue growth [5] Future Outlook - The company is focusing on new product development and expanding its overseas market presence, with overseas revenue for the first half of 2025 reaching approximately 363 million yuan, a growth of 21.33% [5] - The company is expected to benefit from its competitive advantages and continue to capture market share in the overseas market [5]